{"preliminary_commentary":{"by_channel":{"x_thread":36,"youtube":6,"podcast":3,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05226117\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"SURE-01","nct_id":"NCT05226117","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sure-01-nct05226117. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients with muscle-invasive urothelial carcinoma of the bladder, who are suited for and accept radical cystectomy (RC)","label":"Treatment arm","type":"EXPERIMENTAL"}],"collaborators":["High Research"],"completion_date":{"date":"2025-09-24","type":"ACTUAL"},"conditions":["Urothelial Carcinoma"],"enrollment":{"count":44,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sacituzumab govitecan","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-27","lead_sponsor":"IRCCS San Raffaele","official_title":"SURE-01_An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Sacituzumab Govitecan, Before Radical Cystectomy, for Patients With Muscleinvasive Bladder Cancer Who Cannot Receive or Refuse Cisplatin-based Chemotherapy","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-09-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathological complete response","timeFrame":"After the last cycle of the investigational drug (each cycle is 21 days)"}],"references":[{"citation":"Necchi A, de Jong JJ, Maiorano BA, Proudfoot JA, Basile G, Cigliola A, Mercinelli C, Tateo V, Piacentini M, Crupi E, Pastorino GL, Latini G, Tomasi E, Davicioni E, Moschini M, Brembilla G, Colecchia M, de Cobelli F, Ross JS, Madison R, Tambaoan CFB, Briganti A, Montorsi F. Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial. J Clin Oncol. 2026 Jul 20;44(21):2017-2028. doi: 10.1200/JCO-26-00142. Epub 2026 May 31.","pmid":"42218654","type":"DERIVED"}],"start_date":{"date":"2022-03-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT05226117"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sure-01-nct05226117"}